Literature DB >> 2878941

Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.

G Leopold, J Pabst, W Ungethüm, K U Bühring.   

Abstract

The basic pharmacokinetics of bisoprolol were investigated in three independent studies involving 23 healthy volunteers. After administering 20 mg of 14C-bisoprolol orally, mean elimination half-lives of 11 hours for the unchanged drug and 12 hours for total radioactivity were observed. The enteral absorption of bisoprolol was nearly complete. Fifty percent of the dose was eliminated renally as unchanged bisoprolol and the other 50% metabolically, with subsequent renal excretion of the metabolites. Less than 2% of the dose was recovered from the feces. Intraindividual comparison of the pharmacokinetic data measured after oral and intravenous administration of 10 mg bisoprolol to 12 subjects yielded an absolute bioavailability of 90%. Total and renal clearance were calculated as 15.6 L/hr and 9.6 L/hr, respectively. The volume of distribution was 226 L. Concomitant food intake did not influence the bioavailability of bisoprolol.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878941     DOI: 10.1002/j.1552-4604.1986.tb02959.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  27 in total

1.  A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension.

Authors:  M S Dixon; P Thomas; D J Sheridan
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

4.  Bioequivalence and Pharmacokinetics of Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablet versus Bisoprolol 5 mg Tablet and Amlodipine 5 mg Tablet: An Open-Label, Randomized, Two-Sequence Crossover Study in Healthy Chinese Subjects.

Authors:  Chaoying Hu; Xiao Hu; Chunhua Wang; Zirun Zhao; Dan Gao; Xiaoping Chen; Dongli Zhou; Yue Huang; Lin Li; Lan Zhang
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859

5.  Cardioprotective and antiarrhythmic effects of beta-blockers, propranolol, bisoprolol, and nipradilol in a canine model of regional ischemia.

Authors:  T Ogawa; N Hieda; S Sugiyama; T Ito; T Satake; T Ozawa
Journal:  Heart Vessels       Date:  1989       Impact factor: 2.037

Review 6.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 7.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

8.  Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers.

Authors:  C Le Jeunne; J M Poirier; G Cheymol; O Ertzbischoff; F Engel; F C Hugues
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Population pharmacokinetics of bisoprolol in patients with chronic heart failure.

Authors:  Valentina N Nikolic; Tatjana Jevtovic-Stoimenov; Radmila Velickovic-Radovanović; Stevan Ilic; Marina Deljanin-Ilic; Dragan Marinkovic; Svetlana Apostolović; Dragana Stanojevic; Slavoljub Zivanovic; Nikola Stefanovic; Srdjan Pesic; Dejana Ruzic Zecevic; Jasmina R Milovanovic; Slobodan M Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2012-10-24       Impact factor: 2.953

10.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.